Natixis Advisors, L.P. Bridge Bio Pharma, Inc. Transaction History
Natixis Advisors, L.P.
- $68.5 Billion
- Q3 2025
A detailed history of Natixis Advisors, L.P. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 18,948 shares of BBIO stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,948
Previous 13,933
35.99%
Holding current value
$1.26 Million
Previous $602,000
63.46%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BBIO
# of Institutions
447Shares Held
185MCall Options Held
11.3MPut Options Held
1.84M-
Vanguard Group Inc Valley Forge, PA16.8MShares$1.12 Billion0.01% of portfolio
-
Viking Global Investors LP16MShares$1.06 Billion2.36% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY13.3MShares$880 Million27.71% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$826 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X08.74MShares$580 Million0.22% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $9.84B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...